Novartis Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Novartis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count).

1,375 total trials 110 currently recruiting 944 completed early-phase tilt top decile by trial count

Novartis Pharmaceuticals: 1,375 sponsored US clinical trials, 110 recruiting.

Novartis Pharmaceuticals sponsors 1,375 registered US clinical trials on ClinicalTrials.gov, 110 of them currently recruiting, and 944 completed. 470 of these trials are in Phase 3-4 (later-stage) and 776 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 10 trials.

Top-decile sponsor footprint

Novartis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

944 of 1,179 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,375 total, page 9 of 28

TERMINATED Phase 3

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

NCT04210843
COMPLETED

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

NCT05037396
COMPLETED

XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

NCT05157087
COMPLETED Phase 1

A First-in-Human Study of CEE321 in Adult Subjects

NCT04612062
TERMINATED Phase 1

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

NCT04261439
TERMINATED Early Phase 1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

NCT04237649
COMPLETED

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

NCT05541328
COMPLETED Phase 3

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

NCT04209205
COMPLETED Phase 2

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

NCT04164732
TERMINATED Phase 2

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

NCT04065841
TERMINATED Phase 2

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

NCT04066244
COMPLETED Phase 3

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

NCT04156620
COMPLETED Phase 2

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764
TERMINATED Phase 1

A Study of WVT078 in Patients With Multiple Myeloma (MM)

NCT04123418
TERMINATED Phase 2

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

NCT03968419
COMPLETED Phase 2

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

NCT04109313
COMPLETED Phase 2

A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

NCT03938454
TERMINATED Phase 2

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
COMPLETED Phase 2

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525
COMPLETED Phase 3

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
COMPLETED Phase 2

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

NCT04072887
TERMINATED Phase 1

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

NCT04000529
TERMINATED Phase 2

Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients

NCT03944707
COMPLETED Phase 3

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03917472
TERMINATED Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

NCT04035668
TERMINATED Phase 3

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
TERMINATED Phase 3

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
COMPLETED Phase 3

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
TERMINATED Phase 1

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

NCT03940352
COMPLETED Phase 2

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

NCT03822468
TERMINATED Phase 1

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

NCT03876028
COMPLETED Phase 3

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

NCT03954626
COMPLETED Phase 1

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

NCT04665154
COMPLETED Phase 3

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

NCT03769168
COMPLETED Phase 2

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

NCT03926611
TERMINATED Phase 2

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

NCT03946670
COMPLETED Phase 2

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
COMPLETED Phase 3

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

NCT03930641
COMPLETED Phase 1

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

NCT03798626
COMPLETED Phase 3

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

NCT03570892
COMPLETED Phase 3

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

NCT03785405
TERMINATED Phase 2

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

NCT03650400
COMPLETED Phase 2

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

NCT03809611
COMPLETED Phase 3

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT03814187
TERMINATED Phase 2

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

NCT03948334
COMPLETED Phase 3

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

NCT03681093
COMPLETED Phase 3

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03713632
COMPLETED Phase 2

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

NCT03832114
COMPLETED Phase 2

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

NCT03610724
COMPLETED Phase 3

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

NCT03623243
← Previous Page 9 of 28 Next →

Phase Distribution

PhaseTrial count
Phase 1 326
Phase 2 450
Phase 3 393
Phase 4 77

Therapeutic Areas

Non-Small Cell Lung Cancer 10
Breast Cancer 9
Multiple Sclerosis 9
Chronic Spontaneous Urticaria 8
Hypertension 7
Melanoma 7
Relapsing Multiple Sclerosis 6
Carcinoma, Non-Small Cell Lung 6
Hidradenitis Suppurativa 5
Sickle Cell Disease 5

What is open in the Novartis Pharmaceuticals pipeline

110 recruiting of 1,375 indexed (8% open); 944 completed (69%).

Phase mix: 470 late (III/IV) vs 776 early (I/II) (early-phase heavy).

Top condition: Non-Small Cell Lung Cancer (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Novartis Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 1,375 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share Novartis PharmaceuticalsGlaxoSmithKlineEli Lilly and CompanyUniversity of PennsylvaniaUniversity of MichiganArcutis BiotherapeuticsMedtronic EndovascularPenumbraSK Life Science
Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,375 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Novartis Pharmaceuticals page

1,375 registered trials is a research-attention snapshot, not an endorsement of Novartis Pharmaceuticals or any single study.

  • 110 of Novartis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-Small Cell Lung Cancer is the condition Novartis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Novartis Pharmaceuticals pipeline card: 1,375 registered trials from official public datasets.Report a data error.